Our findings lead us to believe that ATP6V0A1 is not only a potential target for therapy in cystinosis, but that ATX has the potential to be repurposed as a ATP6V0A1-inducer and has potential to be used as a combination treatment with cysteamine for the renal pathology in nephropathic cystinosis that persists despite current cystine depletion therapies (Bellomo et al., 2021; Hollywood et al., 2020; Jamalpoor et al., 2021). This evidence concerns the gene ATP6V0A1 and nephropathic cystinosis.